PDH inhibitor CPI‐613 has been approved by FDA for clinical trials for pancreatic cancer treatment.[23] Previous study also indicated that the PC inhibitor CHCA (α‐cyano‐4‐hydroxycinnamic acid) effectively suppressed breast cancer in vivo.[24] Similar results could be observed when MHCC97L cells were treated with PDH or PC inhibitor and glutaminase (GLS) inhibitor BPTES (Figure S3A,B, Supporting Information). The gene discussed is PDP1; the disease is pancreatic neoplasm.